NEUROIMAGING AND CSF BIOMARKER DEVELOPMENT PROGRAM

Funding Agency:
Alzheimer’s Drug Discovery Foundation

The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

Specifically, this RFP focuses on:

  • Developing novel PET ligands for clinical trials
  • Supporting novel CSF biomarkers
  • Validating innovative MRI approaches in larger cohorts
  • Developing novel measures of functional activity such as EEG

Deadlines for Letters of Intent: Feb. 5, 2024; May 13, 2024; Sep. 30, 2024

Agency Website

Eligibility Requirements

Funding is open to researchers and clinicians worldwide at:

  • Academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
  • Biotechnology companies. Existing companies and new startups are both eligible.
  • NOTE: Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones (see Our Research Strategy for more information).

Amount

$600,000

Amount Description

Awad Amount
Up to $600,000 based on stage and scope of research.

Award Duration
One year with potential for follow-on funding.

Funding Type

Grant

Eligibility

Faculty
Medical Fellow/Resident
Post Doctoral Fellows

Category

Engineering and Physical Sciences
Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

February 5, 2024